AIM
HZNP

Aquila Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Aquila Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,000
Closed -$910K – 101
2022
Q4 		$910K Buy
+8,000
New +$664K 0.71% 66
2022
Q3 		– Sell
-5,000
Closed -$399K – 101
2022
Q2 		$399K Hold
5,000
– – 0.28% 85
2022
Q1 		$526K Hold
5,000
– – 0.3% 82
2021
Q4 		$539K Buy
+5,000
New +$545K 0.26% 86

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aquila Investment Management's HZNP Position: Q1 2023 in Review

Aquila Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 8,000 shares — an estimated $910K sold.

Aquila Investment Management first reported a position in HZNP in Q4 2021 and held it in 4 quarters. The position peaked at $910K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Aquila Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Aquila Investment Management sold 8,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $910K.
  • Aquila Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 4 quarters.
  • Aquila Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $910K in Q4 2022.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Aquila Investment Management's 13F filing for Q1 2023, filed 26 Apr 2023.